Paneez Khoury, Florence Roufosse, Fei Li Kuang, Steven J Ackerman, Praveen Akuthota, Bruce S Bochner, Mats W Johansson, Sameer K Mathur, Princess U Ogbogu, Lisa A Spencer, Michael E Wechsler, Nives Zimmermann, Amy D Klion
Rare eosinophil-associated disorders (EADs), including hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis and eosinophilic gastrointestinal disorders, are a heterogeneous group of conditions characterized by blood and/or tissue hypereosinophilia and eosinophil-related clinical manifestations. Although the recent availability of biologic therapies that directly and indirectly target eosinophils has the potential to dramatically improve treatment options for all EADs, clinical trials addressing their safety and efficacy in rare EADs have been relatively few...
March 8, 2024: Journal of Leukocyte Biology